A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
Clinical trial NCT00427830 · COMPLETED
Trial details
- NCT number
- NCT00427830
- Sponsor
- University of Oxford
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2003-05-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.